Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase–producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii …
Abstract The Infectious Diseases Society of America (IDSA) is committed to providing up-to-
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
date guidance on the treatment of antimicrobial-resistant infections. A previous guidance …
Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections
Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …
Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii
M Falcone, G Tiseo, A Leonildi… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter
baumannii (CRAB) infections, but clinical data are limited. This is an observational …
baumannii (CRAB) infections, but clinical data are limited. This is an observational …
International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical …
BT Tsuji, JM Pogue, AP Zavascki… - … : The Journal of …, 2019 - Wiley Online Library
The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
1950s and thus did not undergo contemporary drug development procedures. Their clinical …
[HTML][HTML] Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options
Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible
for hospital-acquired nosocomial infections in the modern healthcare system. Due to the …
for hospital-acquired nosocomial infections in the modern healthcare system. Due to the …
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
R Vázquez-López, SG Solano-Gálvez… - Antibiotics, 2020 - mdpi.com
Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda
Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial …
Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial …
Mechanism of Anti-bacterial Activity of Zinc Oxide Nanoparticle Against Carbapenem-Resistant Acinetobacter baumannii
Acinetobacter baumannii is a multi-drug resistant opportunistic pathogen, which causes
respiratory and urinary tract infections. Its prevalence increases gradually in the clinical …
respiratory and urinary tract infections. Its prevalence increases gradually in the clinical …
New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …
causing substantial morbidity and mortality. Current treatment options for CRAB are limited …
Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii
Antibiotic resistance is one of the biggest challenges for the clinical sector and industry,
environment and societal development. One of the most important pathogens responsible …
environment and societal development. One of the most important pathogens responsible …
Colistin monotherapy versus combination therapy for carbapenem-resistant organisms
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …